| 2026-08-12 | Press release | Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million |
| 2026-08-05 | Press release | Royalty Pharma reports second quarter 2026 results |
| 2026-08-03 | Press release | Royalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives |
| 2026-07-22 | Press release | Royalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from Neurimmune |
| 2026-07-17 | Press release | Royalty Pharma declares third quarter 2026 dividend |
| 2026-07-15 | Press release | Royalty Pharma to announce second quarter 2026 financial results on August 5, 2026 |
| 2026-05-28 | Presentation | Corporate presentation |
| 2026-05-06 | Document | Royalty Pharma reports first quarter 2026 results |
| 2026-05-06 | Presentation | Presentation |
| 2026-05-06 | Press release | Press Release |
| 2026-04-21 | Press release | Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation |
| 2026-04-17 | Press release | Royalty Pharma Declares Second Quarter 2026 Dividend |
| 2026-04-15 | Press release | Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026 |
| 2026-04-14 | ESG report | 2025 Corporate Responsibility Report |
| 2026-03-31 | Press release | Pre-quarterly results communication |
| 2026-03-30 | Press release | Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases |
| 2026-03-23 | Press release | Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence |
| 2026-03-17 | Press release | Royalty Pharma Announces Expansion of Leadership Team |
| 2026-03-02 | Press release | Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma’s Global Platform |
| 2026-03-02 | Press release | Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing |
| 2026-02-26 | Press release | Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference |
| 2026-02-12 | Earnings deck | Q4 2025 Financial Results Presentation |
| 2026-01-20 | Press release | Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 |
| 2026-01-13 | Presentation | J.P. Morgan Healthcare Conference Presentation |
| 2026-01-12 | Press release | Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference |
| 2026-01-09 | Press release | Royalty Pharma Announces Dividend Increase |
| 2025-12-29 | Press release | Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones |
| 2025-12-19 | Press release | Q4 2025 Pre-Quarterly Results Communication |
| 2025-12-16 | Press release | Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million |
| 2025-12-04 | Press release | Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement |
| 2025-11-04 | Presentation | Q3Royalty Pharma Q3 2025 Financial Results |
| 2025-11-04 | Press release | Royalty Pharma Acquires Royalty Interest in Alnylam’s Amvuttra for $310 Million from Blackstone Life Sciences |
| 2025-10-17 | Press release | Royalty Pharma Declares Fourth Quarter 2025 Dividend |
| 2025-10-09 | Press release | Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 |
| 2025-09-29 | Press release | Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director |
| 2025-09-10 | Press release | Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market |
| 2025-09-04 | Press release | Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference |
| 2025-09-02 | Press release | Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes |
| 2025-09-02 | Press release | Royalty Pharma and Zenas Biopharma Enter Into Obexelimab Funding Agreement for Up to $300 Million |
| 2025-08-25 | Press release | Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million |